(VIANEWS) – The NASDAQ ended the session with Castle Biosciences rising 10.35% to $19.93 on Friday, after two successive sessions in a row of losses. NASDAQ rose 1.14% to $16,274.94, following the last session’s upward trend on what was an all-around up trend exchanging session today.
Castle Biosciences’s last close was $18.06, 32.36% under its 52-week high of $26.70.
About Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Earnings Per Share
As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.84.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.94%.
Volume
Today’s last reported volume for Castle Biosciences is 450521 which is 82.86% above its average volume of 246365.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Castle Biosciences’s EBITDA is -65.38.
Sales Growth
Castle Biosciences’s sales growth is 46.8% for the current quarter and 14.7% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Castle Biosciences’s stock is considered to be overbought (>=80).
More news about Castle Biosciences (CSTL).
